NeurogesX to Present at Two November Conferences

SAN MATEO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq:
NGSX), a biopharmaceutical company focused on developing and commercializing
novel pain management therapies, announced today that Anthony DiTonno,
President and Chief Executive Officer, is scheduled to present at two upcoming
conferences in New York City: the Oppenheimer & Co. 20th Annual Healthcare
Conference, to be held November 3-4, 2009 and the Lazard Capital Markets 6th
Annual Healthcare Conference, taking place November 17-18, 2009.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be
available to respond to questions following the presentations and to
participate in one-on-one meetings with investors attending the conferences.

Event: Oppenheimer & Co. Healthcare Conference
Date: Tuesday, November 3, 2009
Time: 3:55 p.m. ET
Place: The Waldorf Astoria Hotel, NYC (East Foyer - Third Floor)

Event: Lazard Capital Markets Healthcare Conference
Date: Tuesday, November 17, 2009
Time: 11:25 p.m. ET
Place: The St. Regis Hotel, NYC (Louis XVI A, Second Floor)

Both presentations will be webcast live and can be accessed by visiting the
investor relations section of NeurogesX' website at www.neurogesx.com. The
webcasts will be archived for 90 days.

About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing
and commercializing novel pain management therapies. Its initial focus is on
chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN),
painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic
neuropathy (PDN). NeurogesX' late stage product portfolio is led by its
product candidate Qutenza(TM), a dermal patch designed to manage pain
associated with peripheral neuropathic pain conditions. Qutenza is currently
approved in the European Union for the treatment of neuropathic pain in
non-diabetic adults, either alone or in combination with other medicinal
products for pain. Qutenza will be marketed in the European Union and certain
countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma
Europe, Ltd. In the United States, NeurogesX submitted a new drug application
(NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was
accepted for filing by the FDA in December 2008 and has been given an extended
Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically
applied, liquid formulation containing a high concentration of capsaicin
designed to treat pain associated with neuropathic pain conditions. NGX-1998
has completed three Phase 1 studies and NeurogesX is currently planning the
design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which
are prodrugs of acetaminophen and various opioids. The company has evaluated
these compounds in vitro and in vivo and is currently seeking development
partners for these programs.

Safe Harbor Statement
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking statements
contained in the Act. Examples of such statements include, but are not limited
to the timing and outcome of regulatory decisions and label approval being
sought or that may be obtained with respect to the NDA for Qutenza with the
FDA, including the PDUFA date for the NDA; plans and timing for
commercialization of Qutenza; and development activities for NGX-1998 and
other product candidates, including regulatory submissions and any outcomes of
such submissions. Such statements are based on management's current
expectations, but actual results may differ materially due to various risks
and uncertainties, including, but not limited to: positive results in clinical
trials may not be sufficient to obtain FDA approval; the FDA may request
additional clinical trials or other information prior to granting approval for
Qutenza; any regulatory approvals which are received may be limited to certain
indications; NeurogesX' product candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy or tolerability; physician or
patient reluctance to use Qutenza or NGX-1998, if approved; and other
difficulties or delays in, clinical development of, and obtaining regulatory
approval for NeurogesX' product candidates. For further information regarding
these and other risks related to NeurogesX' business, investors should consult
NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc. The Ruth Group
Stephen Ghiglieri Sara Pellegrino (investors)
Chief Financial Officer (646) 536-7002
(650) 358-3310 spellegrino@theruthgroup.com

Jason Rando (media)
(646) 536-7025
jrando@theruthgroup.com

SOURCE NeurogesX, Inc.

Stephen Ghiglieri, NeurogesX, Inc., Chief Financial Officer, +1-650-358-3310;
Sara Pellegrino (investors), +1-646-536-7002, spellegrino@theruthgroup.com, or
Jason Rando (media), +1-646-536-7025, jrando@theruthgroup.com, both of The
Ruth Group